Symbols / IFRX $0.91 +1.04% InflaRx N.V.

Healthcare • Biotechnology • Germany • NMS
IFRX Chart
About

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 65.96M
Enterprise Value 20.40M Income -45.63M Sales 29.33K
Book/sh 0.67 Cash/sh 0.64 Dividend Yield —
Payout 0.00% Employees 65 IPO —
P/E — Forward P/E -1.22 PEG —
P/S 2248.82 P/B 1.37 P/C —
EV/EBITDA -0.42 EV/Sales 695.53 Quick Ratio 3.69
Current Ratio 4.13 Debt/Eq 2.16 LT Debt/Eq —
EPS (ttm) -0.79 EPS next Y -0.75 EPS Growth —
Revenue Growth — Earnings 2026-05-06 ROA -45.97%
ROE -88.63% ROIC — Gross Margin 0.00%
Oper. Margin 378.98% Profit Margin 0.00% Shs Outstand 72.29M
Shs Float 60.01M Short Float 4.26% Short Ratio 13.35
Short Interest — 52W High 1.94 52W Low 0.71
Beta 1.51 Avg Volume 400.62K Volume 265.36K
Target Price $8.90 Recom Buy Prev Close $0.90
Price $0.91 Change 1.04%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.89
Mean price target
2. Current target
$0.91
Latest analyst target
3. DCF / Fair value
$-3.69
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.91
Low
$2.00
High
$24.22
Mean
$8.89

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-20 main Guggenheim Buy → Buy $14
2025-12-30 reit HC Wainwright & Co. Buy → Buy $6
2025-12-03 down Leerink Partners Outperform → Market Perform $2
2025-11-10 main Guggenheim Buy → Buy $22
2025-05-29 main Oppenheimer Outperform → Outperform $3
2025-05-08 init Oppenheimer — → Outperform $6
2025-04-29 init Cantor Fitzgerald — → Overweight $10
2025-03-26 main Guggenheim Buy → Buy $10
2025-03-21 reit HC Wainwright & Co. Buy → Buy $8
2025-03-07 reit HC Wainwright & Co. Buy → Buy $8
2025-01-16 reit HC Wainwright & Co. Buy → Buy $8
2024-12-20 reit HC Wainwright & Co. Buy → Buy $8
2024-11-15 reit HC Wainwright & Co. Buy → Buy $8
2024-11-11 reit HC Wainwright & Co. Buy → Buy $8
2024-09-25 reit HC Wainwright & Co. Buy → Buy $8
2024-06-24 reit HC Wainwright & Co. Buy → Buy $8
2024-06-06 reit HC Wainwright & Co. Buy → Buy $8
2024-05-09 reit HC Wainwright & Co. Buy → Buy $8
2024-03-22 reit HC Wainwright & Co. Buy → Buy $8
2024-01-25 main HC Wainwright & Co. Buy → Buy $8
News
RSS: Latest IFRX news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.03
-82.31%
0.17
+162.79%
0.06
0.00
Operating Revenue
0.03
-82.31%
0.17
+162.79%
0.06
0.00
Cost Of Revenue
7.27
+119.10%
3.32
+523.20%
0.53
0.00
Reconciled Cost Of Revenue
7.24
+120.25%
3.29
+595.92%
0.47
0.00
Gross Profit
-7.24
-129.70%
-3.15
-571.66%
-0.47
0.00
Operating Expense
41.02
-17.56%
49.75
+12.76%
44.13
+36.88%
32.24
Research And Development
25.72
-27.27%
35.36
-13.80%
41.02
+9.32%
37.53
Selling General And Administration
17.56
-9.11%
19.33
+19.87%
16.12
+12.40%
14.34
Selling And Marketing Expense
2.05
-49.35%
4.04
+112.01%
1.91
0.00
General And Administrative Expense
15.52
+1.53%
15.29
+7.52%
14.22
-0.88%
14.34
Salaries And Wages
8.94
+5.55%
8.47
+25.63%
6.74
-8.61%
7.37
Other Gand A
5.65
+7.68%
5.25
-5.31%
5.54
+19.49%
4.64
Other Operating Expenses
-2.66
+50.67%
-5.39
+60.15%
-13.53
+32.89%
-20.16
Total Expenses
48.29
-9.02%
53.07
+18.84%
44.66
+38.53%
32.24
Operating Income
-48.26
+8.79%
-52.91
-18.64%
-44.59
-38.33%
-32.24
Total Operating Income As Reported
-48.26
+8.96%
-53.01
-18.04%
-44.91
-39.30%
-32.24
EBITDA
-45.16
+0.86%
-45.55
-8.30%
-42.06
-45.84%
-28.84
Normalized EBITDA
-40.31
+18.11%
-49.22
-22.38%
-40.22
-28.57%
-31.29
Reconciled Depreciation
0.42
-13.53%
0.49
-14.56%
0.57
-4.83%
0.60
EBIT
-45.58
+0.99%
-46.04
-7.99%
-42.63
-44.81%
-29.44
Total Unusual Items
-4.85
-232.20%
3.67
+299.27%
-1.84
-175.42%
2.44
Total Unusual Items Excluding Goodwill
-4.85
-232.20%
3.67
+299.27%
-1.84
-175.42%
2.44
Net Income
-45.63
+0.93%
-46.06
-7.96%
-42.67
-44.71%
-29.48
Pretax Income
-45.62
+0.95%
-46.06
-7.95%
-42.67
-44.71%
-29.48
Net Non Operating Interest Income Expense
7.49
+135.75%
3.18
-15.73%
3.77
+1112.12%
0.31
Interest Expense Non Operating
0.04
+89.97%
0.02
-42.03%
0.04
-21.26%
0.05
Net Interest Income
7.49
+135.75%
3.18
-15.73%
3.77
+1112.12%
0.31
Interest Expense
0.04
+89.97%
0.02
-42.03%
0.04
-21.26%
0.05
Interest Income Non Operating
1.85
-42.27%
3.20
-15.98%
3.80
+525.10%
0.61
Interest Income
1.85
-42.27%
3.20
-15.98%
3.80
+525.10%
0.61
Other Income Expense
-4.85
-232.20%
3.67
+299.27%
-1.84
-175.42%
2.44
Gain On Sale Of Security
-4.85
-232.20%
3.67
+299.27%
-1.84
-175.42%
2.44
Tax Provision
0.01
+135.42%
0.01
0.00
0.00
Tax Rate For Calcs
0.00
+0.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
-1.02
-232.20%
0.77
0.00
0.00
Net Income Including Noncontrolling Interests
-45.63
+0.93%
-46.06
-7.96%
-42.67
-44.71%
-29.48
Net Income From Continuing Operation Net Minority Interest
-45.63
+0.93%
-46.06
-7.96%
-42.67
-44.71%
-29.48
Net Income From Continuing And Discontinued Operation
-45.63
+0.93%
-46.06
-7.96%
-42.67
-44.71%
-29.48
Net Income Continuous Operations
-45.63
+0.93%
-46.06
-7.96%
-42.67
-44.71%
-29.48
Normalized Income
-41.80
+14.63%
-48.96
-19.93%
-40.83
-27.87%
-31.93
Net Income Common Stockholders
-45.63
+0.93%
-46.06
-7.96%
-42.67
-44.71%
-29.48
Diluted EPS
-0.68
+12.82%
-0.78
+0.00%
-0.78
-16.42%
-0.67
Basic EPS
-0.68
+12.82%
-0.78
+0.00%
-0.78
-16.42%
-0.67
Basic Average Shares
67.29
+14.21%
58.92
+7.24%
54.94
+24.28%
44.21
Diluted Average Shares
67.29
+14.21%
58.92
+7.24%
54.94
+24.28%
44.21
Diluted NI Availto Com Stockholders
-45.63
+0.93%
-46.06
-7.96%
-42.67
-44.71%
-29.48
Depreciation Amortization Depletion Income Statement
0.39
-13.87%
0.46
-10.32%
0.51
-3.50%
0.53
Depreciation And Amortization In Income Statement
0.39
-13.87%
0.46
-10.32%
0.51
-3.50%
0.53
Insurance And Claims
0.93
-40.74%
1.57
-18.84%
1.93
-16.98%
2.33
Total Other Finance Cost
-5.68
-5400.79%
-0.10
+67.03%
-0.31
-224.07%
0.25
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
55.22
-27.36%
76.02
-36.76%
120.21
+17.39%
102.40
Current Assets
53.63
-25.15%
71.66
-34.54%
109.47
+12.38%
97.41
Cash Cash Equivalents And Short Term Investments
46.46
-12.08%
52.84
-41.47%
90.27
+10.35%
81.81
Cash And Cash Equivalents
16.02
-12.81%
18.38
+43.92%
12.77
-21.50%
16.27
Cash Equivalents
14.75
+4.52%
14.11
+174.43%
5.14
+150132.35%
0.00
Cash Financial
1.28
-70.08%
4.27
-44.05%
7.63
-53.10%
16.26
Other Short Term Investments
30.44
-11.69%
34.46
-55.54%
77.50
+18.25%
65.54
Receivables
1.43
-17.69%
1.74
-54.23%
3.79
+164.76%
1.43
Taxes Receivable
1.43
-17.69%
1.74
-54.23%
3.79
+164.76%
1.43
Inventory
0.00
-100.00%
6.90
-39.32%
11.37
0.00
Raw Materials
0.00
-100.00%
0.08
-80.62%
0.42
0.00
Work In Process
0.00
-100.00%
6.76
-36.32%
10.61
0.00
Finished Goods
0.00
-100.00%
0.06
-82.84%
0.33
0.00
Prepaid Assets
3.15
-36.87%
4.98
+26.39%
3.94
-66.06%
11.62
Other Current Assets
2.60
-49.96%
5.20
+5463.89%
0.09
-96.34%
2.55
Total Non Current Assets
1.58
-63.74%
4.36
-59.39%
10.74
+115.29%
4.99
Net PPE
1.15
+13.44%
1.01
-25.46%
1.36
-17.03%
1.64
Gross PPE
4.87
+9.17%
4.46
+3.17%
4.33
+4.06%
4.16
Accumulated Depreciation
-3.72
-7.92%
-3.45
-16.32%
-2.97
-17.82%
-2.52
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
3.09
+15.38%
2.68
+0.76%
2.66
+3.17%
2.58
Machinery Furniture Equipment
0.24
+0.00%
0.24
+39.40%
0.17
+39.16%
0.13
Construction In Progress
—
—
0.00
0.00
Other Properties
1.54
-0.20%
1.54
+3.25%
1.49
+2.63%
1.45
Goodwill And Other Intangible Assets
0.04
-16.79%
0.05
-26.21%
0.07
-50.46%
0.14
Other Intangible Assets
0.04
-16.79%
0.05
-26.21%
0.07
-50.46%
0.14
Investments And Advances
0.24
-92.32%
3.09
-65.84%
9.05
+212.07%
2.90
Non Current Prepaid Assets
0.15
-25.97%
0.20
-20.61%
0.26
-16.49%
0.31
Other Non Current Assets
0.00
+0.00%
0.00
—
0.00
Total Liabilities Net Minority Interest
13.66
-6.46%
14.60
-17.16%
17.63
+25.46%
14.05
Current Liabilities
12.98
-8.36%
14.17
-15.90%
16.84
+29.31%
13.03
Payables And Accrued Expenses
5.40
-52.61%
11.39
-4.84%
11.97
+140.09%
4.99
Payables
5.40
-52.61%
11.39
-4.84%
11.97
+140.09%
4.99
Accounts Payable
5.40
-52.61%
11.39
-4.84%
11.97
+140.09%
4.99
Current Accrued Expenses
—
—
—
3.42
Pensionand Other Post Retirement Benefit Plans Current
1.16
-43.61%
2.06
+28.26%
1.61
+22.67%
1.31
Current Debt And Capital Lease Obligation
0.26
-36.72%
0.41
+8.47%
0.37
+1.34%
0.37
Current Capital Lease Obligation
0.26
-36.72%
0.41
+8.47%
0.37
+1.34%
0.37
Current Deferred Liabilities
—
—
0.00
-100.00%
6.21
Current Deferred Revenue
—
—
0.00
-100.00%
6.21
Other Current Liabilities
6.16
+1943.17%
0.30
-89.55%
2.89
+1855.02%
0.15
Total Non Current Liabilities Net Minority Interest
0.68
+55.49%
0.44
-44.30%
0.78
-23.59%
1.02
Long Term Debt And Capital Lease Obligation
0.64
+60.62%
0.40
-46.49%
0.75
-24.47%
0.99
Long Term Capital Lease Obligation
0.64
+60.62%
0.40
-46.49%
0.75
-24.47%
0.99
Other Non Current Liabilities
0.04
+0.00%
0.04
+0.00%
0.04
+0.00%
0.04
Stockholders Equity
41.56
-32.34%
61.42
-40.13%
102.58
+16.11%
88.35
Common Stock Equity
41.56
-32.34%
61.42
-40.13%
102.58
+16.11%
88.35
Capital Stock
8.68
+21.80%
7.12
+0.80%
7.07
+31.72%
5.36
Common Stock
8.68
+21.80%
7.12
+0.80%
7.07
+31.72%
5.36
Share Issued
72.29
+21.80%
59.35
+0.80%
58.88
+31.72%
44.70
Ordinary Shares Number
72.29
+21.80%
59.35
+0.80%
58.88
+31.72%
44.70
Additional Paid In Capital
354.98
+5.99%
334.93
+0.21%
334.21
+18.28%
282.55
Retained Earnings
-377.83
-13.74%
-332.19
-16.10%
-286.13
-17.53%
-243.46
Gains Losses Not Affecting Retained Earnings
48.56
+10.07%
44.12
+10.15%
40.05
+9.32%
36.64
Other Equity Adjustments
48.56
+10.07%
44.12
+10.15%
40.05
+9.32%
36.64
Total Equity Gross Minority Interest
41.56
-32.34%
61.42
-40.13%
102.58
+16.11%
88.35
Total Capitalization
41.56
-32.34%
61.42
-40.13%
102.58
+16.11%
88.35
Working Capital
40.65
-29.29%
57.49
-37.93%
92.62
+9.76%
84.39
Invested Capital
41.56
-32.34%
61.42
-40.13%
102.58
+16.11%
88.35
Total Debt
0.90
+11.53%
0.81
-28.12%
1.12
-17.44%
1.36
Capital Lease Obligations
0.90
+11.53%
0.81
-28.12%
1.12
-17.44%
1.36
Net Tangible Assets
41.51
-32.35%
61.37
-40.14%
102.51
+16.21%
88.21
Tangible Book Value
41.51
-32.35%
61.37
-40.14%
102.51
+16.21%
88.21
Available For Sale Securities
0.24
-92.32%
3.09
-65.84%
9.05
—
Held To Maturity Securities
—
—
9.05
+212.07%
2.90
Investmentin Financial Assets
0.24
-92.32%
3.09
-65.84%
9.05
+212.07%
2.90
Other Equity Interest
7.17
-3.62%
7.44
+0.79%
7.38
+1.72%
7.26
Other Inventories
—
—
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-35.31
+27.27%
-48.56
-28.41%
-37.81
-12.06%
-33.74
Cash Flow From Continuing Operating Activities
-35.31
+27.27%
-48.56
-28.41%
-37.81
-12.06%
-33.74
Net Income From Continuing Operations
-45.63
+0.93%
-46.06
-7.96%
-42.67
-44.71%
-29.48
Depreciation Amortization Depletion
0.42
-13.53%
0.49
-14.56%
0.57
-4.83%
0.60
Depreciation
0.40
-8.90%
0.44
-6.10%
0.47
-5.34%
0.50
Amortization Cash Flow
0.02
-62.16%
0.04
-56.09%
0.10
-2.25%
0.10
Depreciation And Amortization
0.42
-13.53%
0.49
-14.56%
0.57
-4.83%
0.60
Amortization Of Intangibles
0.02
-62.16%
0.04
-56.09%
0.10
-2.25%
0.10
Other Non Cash Items
-1.81
+74.01%
-6.95
-210.17%
-2.24
+18.62%
-2.75
Stock Based Compensation
4.44
+9.32%
4.07
+19.08%
3.41
-43.51%
6.04
Operating Gains Losses
0.70
+1991.26%
-0.04
-108.98%
0.41
+7.18%
0.39
Gain Loss On Investment Securities
-5.68
—
—
—
Net Foreign Currency Exchange Gain Loss
6.39
+17311.43%
-0.04
-108.98%
0.41
+7.18%
0.39
Change In Working Capital
4.86
+313.12%
-2.28
-327.04%
1.00
+110.27%
-9.77
Change In Inventory
6.90
+54.31%
4.47
+139.32%
-11.37
0.00
Change In Payables And Accrued Expense
-5.99
-933.36%
-0.58
-108.30%
6.99
+294.80%
-3.59
Change In Payable
-5.99
-933.36%
-0.58
-108.30%
6.99
+294.80%
-3.59
Change In Other Working Capital
-0.90
-297.93%
0.45
+52.90%
0.30
+564.70%
-0.06
Change In Other Current Assets
4.80
+218.74%
-4.04
-147.20%
8.56
+311.76%
-4.04
Change In Other Current Liabilities
0.06
+102.22%
-2.58
+25.55%
-3.47
-66.77%
-2.08
Investing Cash Flow
3.23
-93.83%
52.36
+395.90%
-17.70
-191.42%
19.36
Cash Flow From Continuing Investing Activities
3.23
-93.83%
52.36
+395.90%
-17.70
-191.42%
19.36
Capital Expenditure
-0.12
-146.83%
-0.05
+42.21%
-0.08
+50.06%
-0.16
Net Investment Purchase And Sale
3.35
-93.61%
52.41
+397.53%
-17.62
-190.24%
19.52
Purchase Of Investment
-46.10
-30.45%
-35.34
+66.04%
-104.05
-61.38%
-64.47
Sale Of Investment
49.45
-43.65%
87.75
+1.52%
86.44
+2.91%
84.00
Net Intangibles Purchase And Sale
-0.12
-146.83%
-0.05
+42.21%
-0.08
+50.06%
-0.16
Purchase Of Intangibles
-0.12
-146.83%
-0.05
+42.21%
-0.08
+50.06%
-0.16
Net Other Investing Changes
-0.00
-200.00%
0.00
—
—
Financing Cash Flow
33.32
+8521.29%
0.39
-99.27%
52.99
+2634.83%
1.94
Cash Flow From Continuing Financing Activities
33.32
+8521.29%
0.39
-99.27%
52.99
+2634.83%
1.94
Net Issuance Payments Of Debt
-0.36
+7.87%
-0.39
-3.78%
-0.37
-2.62%
-0.36
Repayment Of Debt
-0.36
+7.87%
-0.39
-3.78%
-0.37
-2.62%
-0.36
Long Term Debt Payments
-0.36
+7.87%
-0.39
-3.78%
-0.37
-2.62%
-0.36
Net Long Term Debt Issuance
-0.36
+7.87%
-0.39
-3.78%
-0.37
-2.62%
-0.36
Net Common Stock Issuance
22.90
+1985.14%
1.10
-98.06%
56.48
+2303.96%
2.35
Proceeds From Stock Option Exercised
12.92
0.00
-100.00%
0.24
0.00
Net Other Financing Charges
-2.14
-561.83%
-0.32
+90.37%
-3.36
-6940.17%
-0.05
Changes In Cash
1.24
-70.55%
4.19
+266.21%
-2.52
+79.73%
-12.45
Effect Of Exchange Rate Changes
-3.59
-353.84%
1.41
+245.15%
-0.97
-139.56%
2.46
Beginning Cash Position
18.38
+43.92%
12.77
-21.50%
16.27
-38.04%
26.25
End Cash Position
16.02
-12.81%
18.38
+43.92%
12.77
-21.50%
16.27
Free Cash Flow
-35.43
+27.10%
-48.60
-28.26%
-37.89
-11.76%
-33.91
Common Stock Issuance
22.90
+1985.14%
1.10
-98.06%
56.48
+2303.96%
2.35
Interest Paid CFO
-0.03
-63.66%
-0.02
+41.53%
-0.04
+19.85%
-0.04
Interest Received CFO
1.74
-22.51%
2.24
+29.49%
1.73
+34.58%
1.29
Issuance Of Capital Stock
22.90
+1985.14%
1.10
-98.06%
56.48
+2303.96%
2.35
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category